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Background: Accurate assessment of pulmonary status in young children with cystic ﬁbrosis (CF) requires sensitive and objective monitoring
techniques.
Objectives: This study aimed to evaluate the feasibility of lung clearance index (LCI) calculated from multiple breath washout (MBW), home noc-
turnal pulse oximetry and home nocturnal cough recording in young children with CF, and determine whether these tests can distinguish CF pa-
tients from healthy controls.
Methods: We performed a prospective cross-sectional study in 20 CF patients and 30 healthy children aged 0–4 years. MBW was performed in
awake and unsedated children at the outpatient clinic using a commercially available device. Measurements of nocturnal oxygen saturation and
nocturnal cough were done at home using a pulse oximeter and an audiometer.
Results: There was a signiﬁcant difference in mean LCI between healthy children and CF patients (LCI 7.1 vs. 9.3, pb0.001). Nocturnal oxygen
saturation was normal in both groups and did not signiﬁcantly differ between the groups. Similarly, cough showed no differences between both
groups. Cough varied widely between children and between nights. Success rates for saturation and cough measurements were 90% and were sim-
ilar for CF patients and healthy children. Success rate for LCI was 75% for CF patients and 50% for healthy children.
Conclusions: Measurements of LCI, nocturnal oxygen saturation and cough were feasible in young children; however LCI was the only variable
that showed a signiﬁcant difference between children with CF and healthy children.
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sessment for timely identification and treatment of children at
risk of developing irreversible structural lung disease.
For children 6 years and older routine spirometry plays a cen-
tral role in monitoring and management of CF lung disease [4–7].
However, pre-school spirometry in children aged 4–6 years is
challenging since it requires active cooperation. When measured
in a paediatric lung function laboratory using computer-incentive
games, pre-school spirometry is successful in 45–75% of the
children [8–10]. Below the age of 4 years spirometry is even
more difficult, since the average 3.5-year-old child has a develop-
mental level that allows carrying out three-step commands only.
Therefore, the instructions for a forced expiratory spirometry ma-
noeuvre need to be broken down and taught in a manner that is
appropriate to the child's development. Unfortunately, the major-
ity of 2 to 3-year old children are unable to perform pre-school
spirometry. Infant pulmonary function testing (iPFT) can be per-
formed in children b3 years using a baby bodybox. However,
iPFT is time consuming, technically difficult, and requires seda-
tion [11,12]. After 2 years, most children have outgrown the
equipment for iPFT. Consequently, there is a great need for alter-
native non-invasive monitoring instruments for young children.
A promising lung function test to monitor pulmonary disease
in children is multiple breath washout (MBW), which can be per-
formed without sedation and does not require active cooperation
[13–15]. The lung clearance index (LCI) is calculated from
MBW, indicating inhomogeneity of ventilation. Studies have
suggested that LCI is more sensitive than spirometry to detect
early lung disease in patients with CF [15,16]. A study in
young children showed that lung disease indicated by an elevated
LCI starts early in life [17]. However, measurements were per-
formed in children in supine position during sleep after sedation
with chloral hydrate. Sedation makes the test evenmore time con-
suming and necessitates monitoring of patients during sleep.
Therefore we are interested in the feasibility of measuring LCI
in young children, while awake and sitting upright. Disadvan-
tages of MBW include the expensive equipment and requirement
for a lung function laboratory as it is a technically demanding test.
A second test to monitor pulmonary disease in children is home
nocturnal pulse oximetrymeasuring oxygen saturation (SpO2) dur-
ing sleep. A pulse oximeter is relatively cheap, easy to operate, and
can be used across all ages [18–20]. In CF patients with moderate
lung disease and normal awake SpO2, significant nocturnal desa-
turation can occur [21,22]. It is unclear whether nocturnal pulse ox-
imetry can be used as a surrogate endpoint for CF lung disease in
young children, and whether pulse oximetry is sensitive enough to
distinguish between healthy children and children with CF.
A third test to monitor pulmonary disease in children is noc-
turnal cough. Cough is an important component of mucociliary
clearance [23] and is thought to be more frequent in CF com-
pared to healthy control subjects [24,25]. Cough monitoring
has been used in small scale clinical studies [26,27], and can
be monitored at home using relatively simple audiometry. It is
not known whether nocturnal cough monitoring can be used
as a surrogate endpoint in young children.
The aim of our study was to evaluate the feasibility of per-
forming MBW, home nocturnal pulse oximetry, and homenocturnal cough recording in young children. In addition we
compared the sensitivity of these tests to discriminate CF pa-
tients from healthy controls.
2. Methods
2.1. Enrolment
We performed a prospective cross-sectional study to measure
LCI, nocturnal oxygen saturation and nocturnal cough in 20 CF
patients and 30 healthy children aged 0–4 years. CF patients
were recruited from the Paediatric Pulmonology outpatient clinic
at the Erasmus MC — Sophia Children's Hospital Rotterdam.
Healthy children were recruited from three day-care centres in
Rotterdam, located near the Sophia Children's Hospital.
Inclusion criteria for all children were: ages 0–4 years and
weight N8 kg (weight cut-off was selected to standardise MBW
data collection with a single dead space reducer for children
8–20 kg).
Exclusion criteria for all children were: respiratory infection in
the week prior to enrolment, antibiotics for pulmonary symptoms
or hospital admission in the four weeks prior to enrolment, med-
ical conditions that might affect study measurements (e.g. cardiac
problems that can influence saturation), ear–nose–throat related
interventions in the last month (e.g. tonsillectomy, tympanost-
omy tubes, etc.). For healthy children, additional exclusion cri-
teria were: history of chronic pulmonary diseases (such as
asthma, broncho pulmonary dysplasia, and airway malacia), his-
tory of premature birth (b36 weeks of gestation), current pulmo-
nary disease and maintenance use of pulmonary medications.
This study was approved by the local ethics committee and
informed consent was obtained from all parents. This study
was registered in the Dutch trial register (http://www.
trialregister.nl).
2.2. Lung clearance index
MBW tests were performed at the outpatient clinic using a
commercially available device (Exhalyzer®D, Ecomedics,
Switzerland) that was previously described [28,29]. Helium was
used as tracer gas. For technical details see the online supplement.
Measurements were performed while children were awake
and sitting upright, either on their parents' lap or on a chair.
To distract children during measurements we used animations
on a portable DVD player, a favourite book or a toy. In most
children we used a close-fitting facemask (Laerdal® silicone
mask 2). Dead space of the facemask was 24 ml. Only two chil-
dren aged 4 years were able to use a mouthpiece and nose clip
correctly, all other children were measured using a face mask.
Measurements were performed as follows: at the start of a
measurement, subjects breathed normally through the facemask
or mouthpiece. After a stabilization period of minimally 6
breaths, the bias flow automatically switched to the premixed
tracer gas at end expiration, starting the wash-in. Wash-in contin-
ued until equilibrium was reached, defined as a visually stable
plateau of the molar mass signal. The bias flowwas then switched
back to room air to start the washout phase, which was completed
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starting level. Wbreath© software (version 3, 19, 3, ndd Medical
Technologies, Zurich, Switzerland) was used for data acquisition,
storage and analysis.
For each participant we aimed to perform two technically suc-
cessful measurements. After completing the full washout phase,
the minimal time before the next measurement could be started
was three minutes. However, in this young age group many chil-
dren required a longer break to prepare for the next MBW so
often the time between measurements was longer. Data acquisi-
tion and analysis were performed according to published quality
criteria [30–32]. Measurements were accepted when the child
breathed normally during the measurement, and when no leakage
of gas was observed. Additional details on quality control of mea-
surements can be found in the online supplement.
Functional residual capacity (FRC) was calculated from the
cumulative volume of expired tracer gas divided by the difference
between end-tidal gas concentration at the start and end of the
washout. LCI was calculated as the cumulative expired volume
(CEV), divided by the FRC. Since there are no generally accepted
LCI reference values for young children, we defined an abnormal
LCI as a value exceeding 1.96 times the SD above the mean value
for healthy children in this study.
When two successful LCI measurements were obtained in a
patient, the mean of the two measurements was used for ana-
lyses. When only one measurement was successfully obtained
(usually due to poor cooperation for a second measurement),
this measurement was used in the analyses.
2.3. Nocturnal oxygen saturation
Nocturnal SpO2 was measured using a Mars 2001 Pulse
Oximeter (Novametrix, USA) during two separate nights of
sleep at home. This device makes use of a Motion Artefact Rejec-
tion System that filters out artefacts caused by motion or low per-
fusion. Parents were instructed to attach the sensor to the child's
finger or toe and turn on the pulse oximeter when the child went
to bed or shortly after the child fell asleep. The sensor was re-
moved by the parents when the child woke up the following
morning. A registration was considered appropriate for further
analysis when at least 6 h of successful recording was available.
From the stored saturation data we computed mean SpO2 and
two desaturation parameters for each child: D4 desaturations, de-
fined as desaturations of 4% below the mean saturation of the
child; and D90 desaturations, defined as desaturations below
90% SpO2 [18,33]. Number of desaturations was calculated as
well as the total time of D4 and D90 desaturations. For mean
SpO2 a value below 95% was defined as abnormal.
2.4. Cough measurements
Measurements of cough were performed according to a pre-
viously published procedure [24,34]. Cough measurements
were ideally performed on the same nights as the pulse oxime-
try, but at least within two days of the pulse oximetry. Briefly, a
digital audiometer was placed on a stable surface and posi-
tioned close to the child to record all sounds during the night.A sound recording was considered acceptable if at least 6 h of
recording were available.
Sound recordings were transferred from the digital recorder to
a personal computer. All recordings were analyzed using free
open source audio record and edit software, which provided a
graphical display for audio analysis applications (Audacity,
Boston, USA).
An investigator (JCvdM) identified by ear the nature of all
sounds detected by the software on the digital recordings. The be-
ginning of a cough episode was defined as the moment a clear ex-
plosive cough was heard. For each patient the duration of each
cough episode was computed in seconds [24,34,35]. Multiple
cough sounds which occurred in quick succession were counted
as one episode. Such cough episodes were defined to start at the
onset of the first cough sound and end after the last cough (see
Fig. 1 of the online supplement). Finally, from the total duration
of cough seconds and the total time of the recording we computed
the cough seconds per hour (csec/h) for each night.
2.5. Power calculations
There are few data available on LCI, cough and saturation
for children in this age range. Therefore it was not possible to
do a formal power calculation prior to the study. We decided
to invite all CF patients in our centre aged 0–4 years for this
study and estimated that at a 70% response rate the number of
inclusions would be approximately 15 patients. For each CF pa-
tient we aimed to include two healthy controls and thus aimed
to include 30 healthy children. With these numbers, differences
as great as 0.9 SD can be detected for an alpha of 0.05 and a
power of 80%.
2.6. Statistical analysis
Analyses were performed with SPSS (version 15.0) or
STATA (version 11.1) software. For normally distributed data,
values are presented as mean (SD). Non-normally distributed
values are reported as median (range).
Differences between group characteristics were assessed by
independent samples T-test or Mann–Whitney test, as appropri-
ate. Confidence intervals for the differences of medians between
the two groups were calculated by the bootstrap method with
1000 replications. Intraclass Correlation Coefficients (ICC)
were used to assess agreement between repeated measurements.
Spearman's correlation (rs) was used to determine correlations
between LCI, cough and saturation. For all analyses, p-values
of b0.05 were considered statistically significant.
3. Results
Fifty children were included in this study, 20 CF patients
and 30 healthy children aged 0–4 years, all recruited between
July 2008 and March 2010. Baseline characteristics of the chil-
dren did not differ between CF patients and healthy children ex-
cept for BMI, which was lower in CF patients than in healthy
controls (Table 1).
Table 1
Demographics of the study population at inclusion.
CF Healthy
Age (years) 2.4 (1.3) 2.3 (1.0)
Age ranges (years) 0.4–4.9 0.6–4.0
Sex (M/F) 10/10 19/11
Height (Z-score) −0.4 (1.0) −0.5 (1.1)
Weight (Z-score) −0.1 (1.0) 0.8 (0.9)
BMI (Z-score) 0.0 (1.0) 0.9 (1.0)
Pancreatic insufficiency (Y/N) 19/1 N/A
CF mutation (homozygous Phe508del/heterozygous
PheF508del)
13/7 N/A
Data are reported as mean (SD) or as number of subjects. N/A=not applicable.
Fig. 1. Lung clearance index (LCI) in healthy children and cystic fibrosis (CF)
patients. Circles depict healthy children, diamonds depict CF patients. Horizon-
tal bars indicate mean LCI for each group. pb0.001 for the difference in mean
LCI between CF patients and healthy children.
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A successful LCI measurement was obtained in 15/20 CF
patients (75%) and in 15/30 healthy children (50%). There
was a trend towards higher success rate in children with CF
(p=0.08). Reasons for failure included: rejection of the face-
mask, crying and/or talking during the test, irregular breathing
that did not allow further analysis to compute LCI, or the test
did not comply with published quality criteria (see Table 1 of
the online supplement).
Mean LCI was significantly higher in CF patients (LCI=9.3±
1.5) compared to healthy children (LCI=7.1±0.7), with a differ-
ence between the groups of 2.2 (95% CI 1.3–3.1) (pb0.001)
(Table 2 and Fig. 1). LCI showed a good discriminating value be-
tween CF patients and healthy children: the Area Under the
Curve (AUC) of the Receiver Operator Characteristic (ROC)
curve was 0.90 (see Fig. 2 of the online supplement).
In CF patients we obtained two technically successful mea-
surements in 8 patients and one successful measurement in 7
patients. For healthy children we obtained two technically suc-
cessful measurements in 7 children and one successful mea-
surement in 8 children. Since recent guidelines advise to
obtain two LCI measurements per patient, we repeated the anal-
ysis including only the children who performed two measure-
ments. Results were very similar to the primary analysis:
mean LCI was significantly higher in CF patients (LCI=9.1±
1.7) compared to healthy children (LCI=7.2±0.8), with a dif-
ference between the groups of 1.9 (95% CI 0.4–3.4)
(p=0.02). Agreement between LCI measurements in children
from who two measurements could be acquired was good:
Intraclass Correlation Coefficient (ICC)=0.71 (Table 3).Table 2
LCI, oxygen saturation and cough in CF patients and healthy children.
CF
LCI 9.3 (1.5)
Mean SpO2 (%) 97.0 (93.9–98.4)
Time D4 desaturations (s/h) 4.6 (0–369.3)
Time D90 desaturations (s/h) 0.0 (0–254.3)
Number of D4 desaturations (no./h) 0.4 (0–4.7)
Number of D90 desaturations (no./h) 0 (0–3.2)
Cough (s/h) 0.4 (0–6.3)
All data are reported as median (range), except for LCI which is reported as mean (The upper limit of normality for LCI calculated from our
data as (mean+1.96 SD) was 8.4. Using this cut-off, 11/15
CF patients (73%) had an elevated LCI.
FRC results derived from MBW are available in the online
supplement (Table 2).3.2. Nocturnal oxygen saturation
Success rate for saturation measurements was 90%; success-
ful measurements were obtained in 17/20 CF patients and 28/30
healthy children. Reasons for failure included: technical failure
of the device, children not accepting the sensor despite multiple
attempts by the parents, lively movements of a child during
sleep causing a large number of artefacts in the measurement
(see Table 1 of the online supplement).
Mean nocturnal SpO2 values had a median of 97.0% for CF
patients and 97.7% for healthy children (Table 2). There was a
trend towards lower SpO2 in children with CF (p=0.08). Desa-
turations were infrequent in both groups and there were no dif-
ferences in D4 and D90 desaturations between the two groups
(Table 2).
Agreement between SpO2 measurements on two separate
nights was fair: ICC=0.41 and Spearman's rank correlationHealthy Difference (95% CI) p-value
7.1 (0.7) 2.2 (1.3 to 3.1) b0.001
97.7 (95.0–98.8) −0.7 (−1.5 to 0.1) 0.08
13.2 (0–398.4) −8.6 (−22.1 to 32.6) 0.28
1.1 (0–212.4) −1.1 (−5.5 to 1.8) 0.44
0.8 (0–3.9) −0.4 (−1.1 to 0.3) 0.23
0.1 (0–5.2) −0.1 (−0.1 to 0.1) 0.51
0.8 (0–8.9) −0.4 (−1.1 to 0.4) 0.50
SD).
Table 3
Saturation and cough for 2 nights, LCI for 2 measurements.
Test 1 Test 2 ICC (95% CI) (both groups combined)
LCI Healthy 7.1 (0.9) 7.0 (0.7) 0.71 (0.34 to 0.89)
CF 9.4 (1.7) 8.8 (1.6)
Mean SpO2 (%) Healthy 97.7 (91.8–98.9) 97.7 (94.6–98.8) 0.41 (0.12 to 0.64)
CF 96.9 (93.4–98.7) 97.3 (94.4–98.3)
Cough (s/h) Healthy 0.7 (0–8.9) 0.4 (0–4.4) 0.25 (−0.12 to 0.56)
CF 0.4 (0–2.2) 0.2 (0–10.5)
Data are reported as median (range) except for LCI which is reported as mean (SD). ICC=Intraclass Correlation Coefficient.
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nights is shown in Table 3.
Five children had an abnormal nocturnal SpO2 of b95%, in-
cluding one CF patient and three healthy children who had a
mean SpO2 below 95% on one night; and one CF patient who
had a mean SpO2 below 95% on both nights.3.3. Cough
Success rate for cough measurements was 90%; cough reg-
istration was successful in 27/30 healthy children and in 18/
20 CF patients. Reasons for failure included: incorrect handling
of the device by the parents, recording time b6 h, technical fail-
ure, or multiple children sleeping in one room, making individ-
ual cough registration impossible (see Table 1 of the online
supplement).
Median cough seconds per hour (csec/h) was 0.4 for CF pa-
tients and 0.8 for healthy children (Table 2). There was no sig-
nificant difference in csec/h between CF patients and healthy
children (p=0.50). Ranges for nocturnal cough were relativelyFig. 2. Mean saturation measured on two nights. On the Y-axis mean saturation
for the 1st night, on the X-axis the 2nd night. Spearman's rank correlation co-
efficient (rs)=0.5, p=0.001. Open squares depict healthy children; closed cir-
cles depict cystic fibrosis patients. The dotted line shows the line of identity.wide (Table 3). There was poor agreement between csec/h mea-
sured on two separate nights: ICC=0.25.
3.4. Correlations between measurements
LCI did not correlate with mean nocturnal oxygen saturation
or with mean cough, in either healthy children or CF patients.
LCI and mean saturation did not significantly correlate: rs=
−0.28 (p=0.33) for healthy children and rs=0.35 (p=0.25)
for CF patients. For the correlation between LCI and csec/h
rs=−0.23 (p=0.45) for healthy children and 0.06 (p=0.86)
for CF patients.
4. Discussion
In this study we evaluated the feasibility and sensitivity of
LCI, home nocturnal oxygen saturation and home nocturnal
cough measurements to distinguish young CF patients from
healthy controls, and found that all three tests were feasible in
young children; however LCI was the only variable that distin-
guished between children with CF and healthy children.
4.1. LCI
Similar to other studies in older children or adults, we ob-
served that LCI was elevated in 73% of young CF patients rel-
ative to healthy controls. It is generally thought that abnormal
LCI reflects small airways disease. The importance of small air-
ways disease is confirmed by recent papers [36]. A recent study
in young children with CF diagnosed by newborn screening
showed that CT-detected trapped air was present in 50–60%
of infants [1], indicating early small airways disease. A cross-
sectional study in older children showed that elevated LCI
was associated with CT-detected structural lung abnormalities
[16]. The elevated LCI observed in our study is therefore likely
to indicate early CF lung disease. However, the clinical signif-
icance of elevated LCI in young children requires further vali-
dation. Lum et al. performed MBW and raised lung volume
rapid thoraco-abdominal compression measurements in infants
with CF and healthy controls with a mean age of 41 weeks
[17]. In their cohort, lung function abnormalities were detected
in 72% of infants with CF, which is very similar to the elevated
LCI in 73% of CF patients in our study. However, Lum et al.
demonstrated abnormalities in 41% by both techniques per-
formed and in a further 15% by each of the two separate
tests. This suggests that complementary information can be
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thoraco-abdominal compression measurements.
Previous studies of LCI in healthy children [13,14,37,38] re-
port upper limits of normality for LCI between 7.2 and 7.8. Our
calculated upper limit of normality of 8.4 is relatively high.
These differences in observed values may be partially
explained by our younger population. A second explanation is
the current lack of standardization for MBW. To date, there is
no clear international consensus on equipment or procedures
for MBW [39]. For this reason it was suggested that each centre
should produce its own reference values [40]. We therefore in-
cluded a group of healthy children in this study. Recent ATS/
ERS guidelines on pulmonary function testing in preschool
children include a section on LCI [31]. This document only
gives general recommendations on how to perform MBW. It
is stressed that because only a few centres have experience
with MBW, proposals regarding equipment, procedures, analy-
sis, and interpretation must be considered tentative.
An important observation in our study is that we completed
at least one MBW successfully in 75% of the CF patients at
their first visit. We observed a trend towards a higher success
rate for CF patients compared to healthy children, which is
not surprising as 80% of the CF patients were treated with
some form of aerosol therapy, and thus accustomed to a face-
mask. All children were naive to MBW and therefore it is likely
that the success rate can be further increased when children be-
come accustomed to the test if it is routinely performed.
In conclusion, our cross sectional findings support the use of
LCI as a sensitive and feasible monitoring tool to detect CF
lung disease in young CF patients.
4.2. Nocturnal oxygen saturation
Nocturnal oxygen saturation showed a trend towards a
slightly reduced mean saturation in CF patients compared
with healthy children in our study. The relatively small number
of subjects in this study may have been insufficient to detect a
significant difference between SpO2 values in CF patients and
healthy controls. In addition, agreement between measurements
performed on two separate nights was only fair. A previous
study by van der Giessen et al. using nocturnal pulse oximetry
in older children with CF showed moderate agreement in SpO2
between nights (ICC=0.70) [41]. This might be explained by
the fact that the study by van der Giessen was performed in
older children with more advanced disease.
In our study, 2/17 CF patients (12%) and 3/28 healthy chil-
dren (11%) were found to have an abnormal nocturnal SpO2 on
at least one night, with mean SpO2 below 95%. The origin of
these abnormal saturation profiles is not clear. It may demon-
strate normal biological variation, or it might reflect disease.
Desaturations in young CF children can occur due to mucus im-
paction in airways. Younger children are more vulnerable to de-
velop mucus impaction, since their airway diameter is smaller
and central airways can become obstructed more easily. It is
less likely that the observed difference between our study and
that by van der Giessen is of a technical nature, since the
same equipment was used in both studies.Even though we observed only a small difference in mean
nocturnal SpO2 between CF and healthy subjects we still feel
that further exploration of nightly pulse oximetry is warranted.
In previous studies episodes of desaturation were observed
when infants with CF had symptoms of mild airways inflamma-
tion (rhinitis, cough, red throat) [42]. Another study in young
children with CF admitted to the hospital for an infective exac-
erbation showed that nocturnal SpO2 was decreased at admis-
sion and improved with treatment [43]. Based on these
studies and our study we feel that nocturnal pulse oximetry
might be an interesting home monitoring tool to detect a change
in pulmonary condition. A different monitoring regimen might
increase the sensitivity to detect relevant disease. For example
measure SpO2 once every week for a longer period of time,
or measure multiple nights in a row. A previous study by
Kirk et al. demonstrated good agreement between home pulse
oximetry and pulse oximetry performed during laboratory poly-
somnography in children [44]. This indicates that home pulse
oximetry is an accurate method. Overall, pulse oximetry re-
mains an interesting, feasible tool for home monitoring in
young children with CF to detect changes in pulmonary condi-
tion or monitor treatment effects, but further validation studies
are required.
4.3. Cough
Nocturnal cough registration did not show a difference be-
tween CF patients and healthy children in our study. Nocturnal
cough was relatively infrequent in both groups. This low cough
frequency questions whether cough can be a reliable outcome
measure in CF research, as many young patients in our study
show nocturnal cough frequency within normal limits, and
thus cannot improve. Additionally, cough during the first
night did not correlate with cough during the second night, sug-
gesting that cough varies considerably over separate nights.
There are two possible reasons for this poor correlation. First,
average cough frequency was relatively low and therefore in-
sensitive to measure correlation. Second, different types of
cough present in this study might have obscured a possible cor-
relation since cough might be caused by a number of medical
conditions such as respiratory infections, gastro-oesophageal
reflux or allergies.
A major disadvantage of the method we used for cough anal-
ysis is that it is time consuming. We therefore conclude that
cough monitoring in its current form does not seem to be useful
to monitor young CF patients. Cough monitoring might be
more useful in older CF patients, who generally have more re-
spiratory symptoms and might therefore cough more as well. A
study on nocturnal cough in older children with CF showed that
cough increased with age [24].
In conclusion, measurements of LCI, nocturnal oxygen satu-
ration and cough were feasible in young children aged
0–4 years. Mean LCI showed a significant difference between
children with CF and healthy children with good agreement be-
tween repeated measurements in individual children. Nocturnal
SpO2 was normal for both groups, but home pulse oximetry did
detect low saturations in 10% of all children. There was no
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with poor agreement between cough measured on separate
nights, making cough monitoring in its current form unsuitable
for monitoring young children with CF.
Based on the results of this study, LCI seems to be a sensitive
parameter to detect CF lung disease in young children in the
laboratory setting. Further validation of LCI is needed to deter-
mine whether it can be used as a surrogate endpoint for CF
lung disease. In addition further standardization of the methodol-
ogy is needed. Studies on home monitoring of pulse oximetry are
required to further explore the use of this tool to monitor CF lung
disease in young children.Acknowledgements
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